UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13D/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)*

NABI

(Name of Issuer)

Common Stock, par value \$.10 per share

(Title of Class of Securities)

628716102

Jose M. de Lasa, 100 Abbott Park Road Abbott Park, Illinois 60064-6049; Phone 847 937 8905

(CUSIP Number)

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 2, 2000

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box $[_]$.

NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies should be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON		
0. 36-0698440		
A MEMBER OF A GROUP	(a) [] (b) []	
PROCEEDINGS IS REQUIRED P	PURSUANT	
NIZATION		
(7) SOLE VOTING PO 1,630,000 (8) SHARED VOTING 0 (9) SOLE DISPOSITI 1,630,000 (10) SHARED DISPOSI	POWER	
11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
T IN ROW (11) EXCLUDES CER	[]	
13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)		
4.56% (see Item 5 below)		
14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)		
	A MEMBER OF A GROUP PROCEEDINGS IS REQUIRED F IZATION (7) SOLE VOTING PO 1,630,000 (8) SHARED VOTING 0 (9) SOLE DISPOSITI 1,630,000 (10) SHARED DISPOSI 0 OWNED BY EACH REPORTING TIN ROW (11) EXCLUDES CER	

Page 2 of 4 pages

The following information amends and supplements the original Schedule 13D filed by Abbott Laboratories ("Abbott") on October 19, 1992.

ITEM 1. SECURITY AND ISSUER

This statement relates to shares of the common stock, par value \$.10 per share (the "Common Stock"), of NABI, a Delaware corporation (the "Issuer"), whose principal executive offices are located at 5800 Park of Commerce Boulevard N.W., Boca Raton, Florida 33487.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

- (a) As of June 6, 2000, Abbott Laboratories ("Abbott") was the beneficial owner of 1,630,000 shares of Common Stock (the "Shares"), representing approximately 4.56% of the outstanding shares of the Common Stock. The calculation of the foregoing percentage is based on the number of shares of Common Stock shown as being outstanding on the Form 10-Q Quarterly Report filed by the Issuer with the Securities and Exchange Commission for the quarterly period ended April 1, 2000.
- (b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.
- (c) In the past 60 days, Abbott has effected the following open market sales of the Common Stock:

Date	Number of Shares Sold	Average Price Per Share
May 17, 2000	10,000	\$5.6406
May 18, 2000	10,000	\$5.5000
May 19, 2000	25,000	\$5.1750
May 22, 2000	10,000	\$5.2500
May 23, 2000	20,000	\$5.4375
May 24, 2000	20,000	\$5.0000
May 25, 2000	5,000	\$5.3125
May 26, 2000	15,000	\$5.0000
May 30, 2000	40,000	\$5.0781
May 31, 2000	35,000	\$5.5000
June 1, 2000	10,000	\$5.8125
June 2, 2000	40,000	\$5.5781
June 5, 2000	30,000	\$5.3542
June 6, 2000	100,000	\$5.5313

Page 3 of 4 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abbott Laboratories

DATED: June 12, 2000 By: /s/ Gary P. Coughlan

Gary P. Coughlan, Senior Vice President, Finance and Chief Financial Officer

Page 4 of 4 pages